Ongoing Scripps research into polygenic risk for coronary artery disease now offers remote genetic counseling as well as an Android app.
GTC will sequence samples and help with technical and clinical validation, while C2i will perform AI-based analysis of the data, recruit samples, and perform other clinical trial activities.
The Mayo Clinic Platform, now headed by John Halamka, will lean on Nference for multi-omics analytics to inform biomedical R&D and postmarketing surveillance.
Mayo Clinic Ventures and NTT Venture Capital have invested in the AI software developer to synthesize biomedical data for drug development and precision medicine.
In Nature this week: artificial intelligence system is better at spotting breast cancer than experts and a universal sample multiplexing method for single-cell RNA sequencing.
The Guardian reports GlaxoSmithKline is seeking to bolster its use of artificial intelligence in drug development.
The two companies had worked closely together since Parabricks spun out of the University of Michigan in 2015 and entered the Nvidia accelerator program.
The companies are aiming to use microbial biomarkers to predict the development of precancerous adenomas and carcinomas.
The startup company will use the money to develop its microbial tests and AI-based software for surveillance and prevention of hospital-acquired infections.
After comparing manual methods with the firm's pcr.ai tool in more than 20,000 cases, they found that the use of AI improved test accuracy and reliability.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.